Long-term cost-effectiveness of clopidogrel given for up to one year in patients with acute coronary syndromes without ST-segment elevation
William S. Weintraub, MD, FACC*,*,
Elizabeth M. Mahoney, ScD ,
Andre Lamy, MD ,
Steven Culler, PhD*,
Yong Yuan, PhD ,
Jaime Caro, MD||,
Sylvie Gabriel, MD¶,
Salim Yusuf, MD, FACC CURE Study Investigators
* Emory University, Atlanta, Georgia
New England Research Institutes, Watertown, Massachusetts
McMaster University, Hamilton, Ontario, Canada
Bristol-Myers Squibb, Princeton, New Jersey
|| Caro Research Institute, Concord, Massachusetts
¶ Sanofi-Synthelabo, Paris, France
View larger version (37K):
[in a new window]
|
Figure 1 Total costs by treatment group overall and for subgroups based on Medicare costs. Solid bars = placebo; hatched bars = clopidogrel. CI = confidence interval; MI = myocardial infarction.
|
|
View larger version (20K):
[in a new window]
|
Figure 2 Scatterplot of the joint distribution of cost and effectiveness differences in the cost-effectiveness plane using Medicare costs and Framingham life expectancy estimates.
|
|
View larger version (18K):
[in a new window]
|
Figure 3 Cost-effectiveness acceptability curves based on Medicare, MEDSTAT, and Medicare/MEDSTAT costs, and Framingham life expectancy estimates.
|
|
View larger version (28K):
[in a new window]
|
Figure 4 Incremental cost-effectiveness ratio (ICER) both overall and for subgroups based on Medicare costs and both Framingham and Saskatchewan life expectancy estimates. *ICER in women considering life expectancy gains due to the prevention of cardiovascular death rather than all-cause death (in addition to nonfatal stroke and myocardial infarction [MI]): $29,130 on the basis of Framingham; $49,369 on the basis of Saskatchewan. LYG = life-year gained.
|
|
|
